Luteolin prevents TNF-α-induced NF-κB activation and ROS production in cultured human placental explants and endothelial cells
Placenta · 2024
DOI: 10.1016/j.placenta.2023.12.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Placenta, 2024. Verfasst von Adrian C Eddy und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Chicago, IL, USA. Hauptthemen laut MEDLINE: Pre-Eclampsia, Hypertension. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIGMS NIH HHS, NHLBI.
Abstract (Originalsprache)
INTRODUCTION: Preeclampsia (PE) is a serious hypertensive pregnancy disorder and a leading cause of maternal and perinatal morbidity and mortality. Despite the prevalence and complications, there are no approved therapeutics to relieve PE symptoms. Inflammation, oxidative stress, and angiogenic imbalance have been shown to contribute to the PE pathophysiology, though there is a lack of understanding in how best to target these pathways in PE. We recently demonstrated that the bioflavonoid luteolin is a potent inhibitor of the anti-angiogenic and pro-hypertensive soluble fms-like tyrosine kinase 1 (sFlt-1), and here we aimed to determine if luteolin was also capable of reducing inflammation and oxidative stress pathways. METHODS: Tumor necrosis factor (TNF)-α, which is upregulated in PE, was utilized to stimulate these pathways in human placental explants and endothelial cells. Endothelin-1 (ET-1) and interleukin (IL)-6 in the media from explants and cells were measured via ELISA, and NF-κB localization and reactive oxygen species were detected via fluorescence microscopy. RESULTS: Pretreatment with luteolin demonstrated significant reductions in NF-κB activation, reactive oxygen species, superoxide, and IL-6 and ET-1 expression in endothelial cells. We also saw a significant reduction in phosphorylation of NF-κB in human placental explants. DISCUSSION: These data demonstrate that luteolin inhibits pathways implicated in the development of PE and should be explored further for its potential as a PE therapeutic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Chicago, IL, USA.
- Department of Gynecology and Obstetrics, Emory University, Atlanta, GA, USA.
- Department of Surgery and Department of Pharmacology & Toxicology, University of Mississippi Medical Center, Jackson, MS, USA.
- Department of Physiology, University of Mississippi Medical Center, Jackson, MS, USA.
- Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Chicago, IL, USA. Electronic address: srana@bsd.uchicago.edu.
Förderung
- NHLBI NIH HHS
- NIGMS NIH HHS
- NHLBI
- National Institutes of Health
- National Institute of General Medical Sciences
Zitieren
APA
Eddy, A. C., Rajakumar, A., Spradley, F. T., Granger, J. P., & Rana, S. (2024). Luteolin prevents TNF-α-induced NF-κB activation and ROS production in cultured human placental explants and endothelial cells. Placenta. https://doi.org/10.1016/j.placenta.2023.12.004
Vancouver
Eddy AC, Rajakumar A, Spradley FT, Granger JP, Rana S. Luteolin prevents TNF-α-induced NF-κB activation and ROS production in cultured human placental explants and endothelial cells. Placenta. 2024. doi:10.1016/j.placenta.2023.12.004
BibTeX
@article{Eddy2024,
author = {Eddy, Adrian C and Rajakumar, Augustine and Spradley, Frank T and Granger, Joey P and Rana, Sarosh},
title = {Luteolin prevents TNF-α-induced NF-κB activation and ROS production in cultured human placental explants and endothelial cells},
journal = {Placenta},
year = {2024},
doi = {10.1016/j.placenta.2023.12.004}
}
EUVIMED